Artiva Biotherapeutics (ARTV) Operating Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Operating Expenses data on file, last reported at $24.4 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $24.4 million, up 10.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.1 million (up 22.82% YoY), and the FY2025 annual result was $89.8 million, up 32.99% from the prior year.
• Operating Expenses improved to $24.4 million in Q1 2026 per ARTV's latest filing, from $21.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $24.4 million in Q1 2026 and troughed at $14.3 million in Q4 2023.
• A 4-year average of $18.9 million and a median of $18.3 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses advanced 5.67% in 2024, then jumped 50.38% in 2025.
• A 4-year view of Operating Expenses shows it stood at $14.3 million in 2023, then rose by 27.56% to $18.3 million in 2024, then gained by 20.06% to $21.9 million in 2025, then rose by 11.39% to $24.4 million in 2026.
• Business Quant data shows ARTV's Operating Expenses at $24.4 million in Q1 2026, $21.9 million in Q4 2025, and $22.9 million in Q3 2025.